Home  |  About SITC  |  Twitter  |  LinkedIn  |  YouTube  |  Oncology Tube  |  Sitemap

Immunoscore Project

The outcome prediction in cancer is usually achieved by evaluating tissue samples obtained during surgical removal of the primary tumor and focusing on their histopathological characteristics. Tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N), and evidence for metastases (M). However, it is recognized that cancer outcomes can vary significantly among patients within the same stage. This classification provides limited prognostic information in estimating the outcome in cancer and does not predict response to therapy.

Recently, many reports suggest that cancer development is controlled by the host’s immune system, underlying the importance of including immunological biomarkers for the prediction of prognosis and response to therapy, a concept that has been termed “immunoscore”. Data collected from large cohorts of human cancers demonstrated that the immune-classification has a prognostic value that may add significantly to the AJCC/UICC TNM-classification. Thus, it is imperative to begin incorporating immune scoring as a prognostic factor and to introduce this parameter as a marker to classify cancers, as part of the routine diagnostic and prognostic assessment of tumors. At the same time, the inherent complexity of quantitative immunohistochemistry, in conjunction with variable assay protocols across laboratories, the different immune cell types analyzed, different region selection criteria, and variable ways to quantify immune infiltration underscore the urgent need to reach assay harmonization.

In an effort to promote the immunoscore in routine clinical settings, a worldwide task force was initiated. Led by SITC, this task force is comprised of the European Academy of Tumor Immunology; the Cancer and Inflammation Program; the National Cancer Institute, National Institutes of Health, USA; and La Fondazione Melanoma. The results of this global validation may result in the implementation of the immunoscore as a new component for the classification of cancer. This task force met in Naples, Italy on February 13, 2012, to gain consensus on the framework of a retrospective evaluation of immunoscore as a prognostic biomarker for patients with colon cancer.

The SITC-led Immunoscore Project was initiated with 23 centers in the following countries:

  • Austria
  • Canada
  • China
  • Czech Republic
  • France
  • Germany
  • India
  • Italy
  • Japan
  • The Netherlands
  • Qatar
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
  • United States

Immunoscore Steering Committee

  • Paolo Ascierto, MD - Instituto Nazionale Tumori-Fondazione 'G. Pascale'
  • Carlo Bifulco, MD - Providence Portland Medical Center
  • Bernard A. Fox, PhD - Earle A. Chiles Research Institute
  • Jerome Galon, MD - Inserm, Cordeliers Research Center
  • Francesco Marincola, MD - Sidra Medical and Research Center

Principal Investigator

Jérôme Galon, PhD - INSERM, Cordeliers Research Center, Paris, France

Co-Principal Investigator

Franck Pagès, MD, PhD - Immunomonitoring plateform, Georges Pompidou European Hospital, Paris, France
INSERM, Cordeliers Research Center, Paris, France

Upcoming Immunoscore Events

Immunoscore Presentation at the 2016 ASCO Annual Meeting
Here the latest results from the Immunoscore project presented by Dr. Jérôme Galon during the Gastrointestinal (Colorectal) Cancer Oral Abstract Session on Sunday Jun 05, 2016 at 8:00am.

For the full abstract and session details visit: Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients

Past Immunoscore Events

Immunoscore Updates session at the STIC 29th Annual Meeting
November 8, 2014 – National Harbor, MD

Melanoma Bridge 2014
December 3-6, 2014 –Naples, Italy
Symposium jointly organized by SITC, Istituto Nazionale Tumori Fondazione "G. Pascale", Fondazione Melanoma Onlus, Sidra Medical and Research Center
For more information, visit: http://www.melanomabridge.org/

Immunoscore Slide Sharing Portal kick-off call and PathForceDx online training session
August 13, 2014
Participating Centers from across Europe, Asia, and North America met online to explore PathForceDx software functions and to discuss ideas and best practices for sharing slides and data.

Natural and Therapy-induced Anticancer Immunosurveillance: The Immunoscore
July 3-4th 2014 – Paris, France

Updates on Immunotherapy of Cancer and Immunoscore
January 23-24, 2014 – Doha, Qatar
View presentations from this program as well as meeting abstracts published in JITC.

Melanoma Bridge Meeting: The Immunoscore in Cancer
December 2013 – Naples, Italy

2013 SITC Annual Meeting
November 7-10, 2013 – National Harbor, MD
View video and presentation slides from this program

World Immunoscoring Meeting
December 4th 2012 – Naples, Italy
Supported by SITC, Melanoma Foundation and EATI

World Immunotherapy Council Meeting
February 20-21, 2012 – Curacao, The Netherlands
Supported by SITC

The Immunoscore as a Novel Approach for the Classification of Cancer Patients
February 4th 2012 – Naples, Italy
Supported by SITC, Melanoma Foundation and EATI

Learn More About the Immunoscore Project

Support the Immunoscore Project

To offer financial support to the Immunoscore project, please contact the SITC Executive Office at (414) 271-2456 or info@sitcancer.org.

This initiative has been made possible by the generous support of the following companies:

Slide-sharing portal powered by PathForceDX.



Society for Immunotherapy of Cancer
555 East Wells Street, Suite 1100  |  Milwaukee, WI 53202-3823 USA
Tel: +1 414 271 2456  |  Fax: +1 414 276 3349  |  Email: info@sitcancer.org
About SITC  |  Membership  |  Journal  |  Meetings  |  Resources  |  Support SITC
© 2016 Society for Immunotherapy of Cancer. All rights reserved.